Diabetics on both sides of the Atlantic might be a very happy set of people as AstraZeneca and Bristol-Myers Squibb announced that its new drug dapagliflozin has been approved for a regulatory review. Apparently, the medicine has been given the green signal for the companies’ marketing authorization application for the therapy.

It needs to be noted that dapagliflozin has been developed to treat people suffering from type 2 diabetes. The drug basically revolves around controlling the glucose levels of independent insulin pathways.

The submissions made by the two organizations are supported by clinical trials that were carried out by the two organizations over a period of two years. Data related to over 40 studies was submitted and had involved the participation of a total of 6,000 patients.

The drug was produced in collaboration between AstraZeneca and Bristol-Myers Squibb, who had started their collaboration in 2007. In the previous month, Astra Zeneca had made a new deal with an organization known as Galderma; the partnership will only involve research regarding the treatment for skin conditions.

The new development must be a whiff of fresh air for people suffering from diabetes, as figures available with the International Diabetes Federation; an estimated 285 million people suffer from the condition all over the world. The numbers are predicted to cross 438 million by 2030.